Document is current
Any future updates will be listed below
-
Authors
Sakamoto, Yuma
Ishida, Takashi
Masaki, Ayako
Murase, Takayuki
Ohtsuka, Eiichi
Takeshita, Morishige
Muto, Reiji
Choi, Ilseung
Iwasaki, Hiromi
Ito, Asahi
Kusumoto, Shigeru
Nakano, Nobuaki
Tokunaga, Masahito
Yonekura, Kentaro
Tashiro, Yukie
Suehiro, Youko
Iida, Shinsuke
Utsunomiya, Atae
Ueda, Ryuzo
Inagaki, Hiroshi
-
Funding
Funding for this research was provided by:
Grants-in-Aid for Early-Career Scientists (22K15426)
Grants-in-Aid for Scientific Research (24K11570)
Nippon Shinyaku Research Grant
Ichiro Kanehara Foundation for the Promotion of Medical Sciences and Medical Care
Grant-in-Aid for Challenging Research (21K19900)
Grant-in-Aid for Scientific Research (22H02918)
Grants-in-Aid from the Japan Agency for Medical Research and Development (21ae0101074h0001, 22ae0101074h0001)
- License Information
-
More Information
Article History
Received: 13 June 2024
Revised: 5 November 2024
Accepted: 10 November 2024
First Online: 25 November 2024
Declarations
:
: Hiromi Iwasaki received research funding from Kyowa Kirin Co., Ltd. and honoraria from AbbVie, AstraZeneca, Chugai, Ono, Takeda, Janssen, Sanofi, SymBio and Daiichi Sankyo Co., Ltd. Shigeru Kusumoto received research funding from Chugai Pharmaceutical Co., Ltd., and Daiichi Sankyo Co., Ltd., and received honoraria from Chugai Pharmaceutical Co., Ltd. and Kyowa Kirin Co., Ltd. Nobuaki Nakano received honoraria from Novartis, Takeda pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Celgene, Otsuka Pharmatceutical Co., Ltd., Nippon Shinyaku Co., Ltd., Kyowa Kirin Co., Ltd., and Asahi Kasei Pharma Co., Ltd., and received consulting fee from JIMRO. Kentaro Yonekura received honoraria from AbbVie, Amgen, Daiichi Sankyo Co., Ltd., Eisai, Eli Lilly Japan, Janssen Pharmaceuticals, Kaken Pharmaceutical, Kyowa Kirin Co., Ltd., Maruho, Meiji Seika Pharma, Minophagen Pharmaceutical, Mundipharma, Novartis, Otsuka Pharmaceutical, Sun Pharma Japan, Sanofi, Taiho Pharmaceutical, Torii Pharmaceutical, and UCB Japan. Youko Suehiro received honoraria from Chugai Pharmaceutical, Abbvie, Sanofi, Ono, Janssen Pharmaceutical, Genmab, Kyowa Kirin, Bristol-Myers, Meiji Seika Pharma, Nippon Shinyaku, and Nippon Kayaku, and received consulting fees from JIMRO. Shinsuke Iida received honoraria from Janssen, Bristol-Myers Squibb, Ono, Takeda, and Sanofi, and received research funding from Sanofi, Chugai, Ono, Takeda, Janssen, Bristol-Myers Squibb, Abbvie, Novartis, Amgen, Daiichi Sankyo, Otsuka, Celgene, Alexion and Glaxo-Smith-Klein. Atae Utsunomiya received honoraria from Meiji Seika Pharma Co., Ltd., Kyowa Kirin Co., Ltd., Daiichi Sankyo Co., Ltd., and Bristol-Myers, and received consulting fees from HUYA Japan, JIMRO, Meiji Seika Pharma Co., Ltd. and Otsuka Medical Devices Co., Ltd. Ryuzo Ueda reports grants from Kyowa Kirin Co., Ltd., Chugai Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd. and other support from Sustainable Cell Therapeutics Co., Ltd. outside the submitted work. The other authors have no COI to disclose.
: The present study was approved by the institutional ethics committees of Nagoya City University Graduate School of Medical Sciences (Nagoya, Japan), Nagoya University Graduate School of Medicine (Nagoya, Japan), Oita Prefectural Hospital (Oita, Japan), Fukuoka University (Fukuoka, Japan), National Hospital Organization Kyushu Cancer Center (Fukuoka, Japan), National Hospital Organization Kyushu Medical Center (Fukuoka, Japan), and Imamura General Hospital (Kagoshima, Japan). All patients registered to the present study provided written informed consent before tumor sampling according to the Declaration of Helsinki.
